Bionano Genomics Inc. (BNGO)
Bionano Genomics Statistics
Share Statistics
Bionano Genomics has 2.73M shares outstanding. The number of shares has increased by 86.48% in one year.
| Shares Outstanding | 2.73M |
| Shares Change (YoY) | 86.48% |
| Shares Change (QoQ) | 18.6% |
| Owned by Institutions (%) | 17.39% |
| Shares Floating | 2.72M |
| Failed to Deliver (FTD) Shares | 25.54K |
| FTD / Avg. Volume | 11.6% |
Short Selling Information
The latest short interest is 9.83M, so 421.76% of the outstanding shares have been sold short.
| Short Interest | 9.83M |
| Short % of Shares Out | 421.76% |
| Short % of Float | 423.78% |
| Short Ratio (days to cover) | 3.81 |
Valuation Ratios
The PE ratio is -16.66 and the forward PE ratio is -0.18. Bionano Genomics's PEG ratio is -0.34.
| PE Ratio | -16.66 |
| Forward PE | -0.18 |
| PS Ratio | 107.23 |
| Forward PS | 0.1 |
| PB Ratio | 40.27 |
| P/FCF Ratio | -30.52 |
| PEG Ratio | -0.34 |
Enterprise Valuation
Bionano Genomics Inc. has an Enterprise Value (EV) of 99.43M.
| EV / Earnings | -0.43 |
| EV / Sales | 2.75 |
| EV / EBITDA | -0.47 |
| EV / EBIT | -0.46 |
| EV / FCF | -0.78 |
Financial Position
The company has a current ratio of 1.4, with a Debt / Equity ratio of 0.83.
| Current Ratio | 1.4 |
| Quick Ratio | 1.17 |
| Debt / Equity | 0.83 |
| Total Debt / Capitalization | 45.23 |
| Cash Flow / Debt | -1.58 |
| Interest Coverage | -42.05 |
Financial Efficiency
Return on equity (ROE) is -2.42% and return on capital (ROIC) is -122.63%.
| Return on Equity (ROE) | -2.42% |
| Return on Assets (ROA) | -1.08% |
| Return on Capital (ROIC) | -122.63% |
| Revenue Per Employee | $104,988.37 |
| Profits Per Employee | $-675,851.74 |
| Employee Count | 344 |
| Asset Turnover | 0.17 |
| Inventory Turnover | 1.16 |
Taxes
| Income Tax | 62K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -94.5% in the last 52 weeks. The beta is 2.25, so Bionano Genomics's price volatility has been higher than the market average.
| Beta | 2.25 |
| 52-Week Price Change | -94.5% |
| 50-Day Moving Average | 9.14 |
| 200-Day Moving Average | 25.76 |
| Relative Strength Index (RSI) | 26.35 |
| Average Volume (20 Days) | 220.08K |
Income Statement
In the last 12 months, Bionano Genomics had revenue of 36.12M and earned -232.49M in profits. Earnings per share was -6.81.
| Revenue | 36.12M |
| Gross Profit | 9.57M |
| Operating Income | -215.25M |
| Net Income | -232.49M |
| EBITDA | -213.6M |
| EBIT | -215.25M |
| Earnings Per Share (EPS) | -6.81 |
Balance Sheet
The company has 17.95M in cash and 79.41M in debt, giving a net cash position of -61.47M.
| Cash & Cash Equivalents | 17.95M |
| Total Debt | 79.41M |
| Net Cash | -61.47M |
| Retained Earnings | -581.21M |
| Total Assets | 87.36M |
| Working Capital | 14.03M |
Cash Flow
In the last 12 months, operating cash flow was -125.18M and capital expenditures -1.69M, giving a free cash flow of -126.87M.
| Operating Cash Flow | -125.18M |
| Capital Expenditures | -1.69M |
| Free Cash Flow | -126.87M |
| FCF Per Share | -3.72 |
Margins
Gross margin is 26.49%, with operating and profit margins of -595.98% and -643.74%.
| Gross Margin | 26.49% |
| Operating Margin | -595.98% |
| Pretax Margin | -643.57% |
| Profit Margin | -643.74% |
| EBITDA Margin | -591.44% |
| EBIT Margin | -595.98% |
| FCF Margin | -351.29% |
Dividends & Yields
BNGO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -170.68% |
| FCF Yield | -1163.53% |
Analyst Forecast
The average price target for BNGO is $60, which is 1403.8% higher than the current price. The consensus rating is "Hold".
| Price Target | $60 |
| Price Target Difference | 1403.8% |
| Analyst Consensus | Hold |
| Analyst Count | 3 |
Stock Splits
The last stock split was on Aug 7, 2023. It was a backward split with a ratio of 1:10.
| Last Split Date | Aug 7, 2023 |
| Split Type | backward |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | -14.95 |
| Piotroski F-Score | 3 |